AML is a silent but deadly blood cancer that’s claiming Indian lives due to delayed diagnosis and lack of access, here’s what ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a ...

Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is a biologically aggressive and diagnostically complex leukemia subtype—especially prevalent in pediatric and therapy-related ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, ...

A Kura Oncology and Kyowa Kirin-partnered drug vying to become the first FDA-approved treatment for cases of acute myeloid leukemia (AML) carrying a particular genetic signature will have its ...

Kura Oncology showed off new Phase II data for its acute myeloid leukemia drug and, at about the same time, got its New Drug Application accepted at the FDA with a PDUFA date set for late this year.

The trial of ziftomenib enrolled 92 heavily pretreated patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura and Kyowa announced back in February that the ...

acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of ...